11:00am
to
12:00pm |
|
Whole Genome Studies to Identify Genetic Variants Associated with Chemotherapy
(VTC)
Eileen Dolan, PhD
Professor of Medicine, Section of Hematology/Oncology
Co-Director, Clinical and Experimental Therapeutics Program of the Comprehensive Cancer Center
University of Chicago
Chicago, Illinois
A seminar in the Research Institute Seminar Series
A primary aim of pharmacogenomics has been to devise novel personalized pharmacological treatment strategies based on an individual's genetic makeup that maximize the potential for therapeutic benefit and minimize the risk of adverse side effects for any given medication. The potential cost savings (through increased drug efficacy) and decreased morbidity and mortality (through increased drug safety) is immense. Advances in DNA sequencing and polymorphism characterization technologies have driven the field from a hypothesis-driven approach to a discovery-oriented, genome-wide approach that requires few assumptions about which variants are most relevant for the outcome. Personalized drug therapy is especially desirable in oncology, in which the therapeutic index is narrow - that is, with little difference between toxic and therapeutic doses - and drug toxicity can be life-threatening. This presentation will cover the role of pharmacogenomics in cancer research and the newest approaches to identify genetic variants that contribute to variation in response and toxicity of chemotherapeutics.
Live Webcast: http://research.vtc.vt.edu/live-webcast
Hosted by: Michael J. Friedlander, PhD, Executive Director, Virginia Tech Carilion Research Institute
More information...
|
540-526-2013